MwanzoGLTO • NASDAQ
add
Galecto Inc
Bei iliyotangulia
$ 5.14
Bei za siku
$ 4.99 - $ 5.31
Bei za mwaka
$ 4.40 - $ 23.50
Thamani ya kampuni katika soko
6.70M USD
Wastani wa hisa zilizouzwa
elfu 19.06
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Defense World
siku 1 iliyopita
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA)
0.00%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.84M | -34.42% |
Mapato halisi | -3.88M | 52.27% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -3.39 | 32.03% |
EBITDA | -3.83M | 32.07% |
Asilimia ya kodi ya mapato | -0.18% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 19.68M | -55.46% |
Jumla ya mali | 23.38M | -53.29% |
Jumla ya dhima | 2.44M | -80.73% |
Jumla ya hisa | 20.94M | — |
hisa zilizosalia | 1.32M | — |
Uwiano wa bei na thamani | 0.31 | — |
Faida inayotokana na mali | -37.89% | — |
Faida inayotokana mtaji | -43.02% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -3.88M | 52.27% |
Pesa kutokana na shughuli | -3.65M | 56.81% |
Pesa kutokana na uwekezaji | 0.00 | -100.00% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | -3.18M | -2,709.84% |
Mtiririko huru wa pesa | -2.08M | 44.50% |
Kuhusu
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2011
Makao Makuu
Tovuti
Wafanyakazi
13
